Virtue Insight brought first Pharma Regulatory 2018 scheduled on 15th March in Mumbai, focusing on the clarification and interpretation to the most critical regulatory guidelines faced by the Indian Pharma companies. Accuprec Research Labs partcipated in the mega event as an exhibitor. Team of Accuprec - Dr Manish Rachchh, Director & CEO, Dr Rina Gokani, Director & CSO as well as Sagar Bhut, Research Associate, Regulatory Affairs participated in the event.
This one day strategical summit provided insights on the US, Europe and ROW region which presents the major revenue of the top Indian pharmaceutical companies. In order to succeed in this new environment, it is critical to be up to date on regulatory hurdles and be transparent in all regulatory process. The summit featured government and regulatory authorities and expert insights to help you tackle and overcome these regulatory challenges, and to improve the drug and device approval processes for pharmaceutical, biopharmaceutical and medical device companies.
Keynote speaker SHANTANU MUKHERJEE, Legal Head, #Asia Pacific and Japan, @LupinLimited speaking about Adapt or Perish: Big Pharma in 2017
Keynote speaker RAHUL GUPTA, Vice President, #Regulatory Affairs, #USV speaking about Elemental Impurities (ICH Q3D) compliance
Keynote speaker AMITA BHAVE, Head #Regulatory Affairs GDD India, @Novartis speaking about #Clinical #research - recent positive #regulatory scenario
Panel Discussion: Registration, Compliance and Approval – What next? Moderator : SNEHA ARYA, Panellists: MAYUR PARMAR, ALAP GANDHI, SRIRUPA DAS and AJIT PATIL
Keynote speaker RAJENDRA SANGHAVI, Sr. Consulting #Clinician & Chairman - #Medical Committee, Indian Drug Manufacturers’ Association (#IDMA) speaking on FDCs: Panacea or Pandora’s Box